Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment

Faraoni, Erika Y.; McAllister, Florencia

doi:10.1158/1078-0432.CCR-23-3295

Article navigation

CCR Translations| June 03 2024

Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment

Erika Y. Faraoni

0000-0003-0731-2122

;

Erika Y. Faraoni

1Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Florencia McAllister

0000-0002-9915-0943

Florencia McAllister *

2Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

3Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.

4Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

*Corresponding Author: Florencia McAllister, Department of Genetics, University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Houston, TX 77030. E-mail: [email protected]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: Florencia McAllister, Department of Genetics, University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Houston, TX 77030. E-mail: [email protected]

Clin Cancer Res 2024;30:2297–9

Received: January 29 2024

Revision Received: February 21 2024

Accepted: March 08 2024

Online ISSN: 1557-3265

Print ISSN: 1078-0432

Funding

Funding Group:

Award Group:
- Funder(s):
  Andrew Sabin Family Foundation
- Principal Award Recipient(s):
  F.
  
  McAllister
Award Group:
- Funder(s):
  Cancer Prevention and Research Institute of Texas (CPRIT)
- Award Id(s):
  RP200173
- Principal Award Recipient(s):
  F.
  
  McAllister
Award Group:
- Funder(s):
  National Cancer Institute (NCI)
- Award Id(s):
  1R37CA237384
- Principal Award Recipient(s):
  F.
  
  McAllister
Award Group:
- Funder(s):
  V Foundation for Cancer Research (VFCR)
- Principal Award Recipient(s):
  F.
  
  McAllister

2024

American Association for Cancer Research

Clin Cancer Res (2024) 30 (11): 2297–2299.

https://doi.org/10.1158/1078-0432.CCR-23-3295

Summary

KRT17-high intermediate cell population with elevated CXCL8 expression informed elevated myeloid infiltration status in tumors and associated with protumorigenic signatures in peripheral granulocytes from patients with pancreatic cancer. Furthermore, CXCL8 plasma levels were found to resemble KRT17⁺/CXCL8⁺ abundance in tumors, in which higher levels predicted worse patient outcomes.

2024

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment

Summary

Citing articles via

Email alerts

AACR Journals

Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment

Summary

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only